Degang Liu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Degang Liu

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

British Journal of Cancer|April 19, 2025

Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancerXin Li, Kenza Mamouni, Rui Zhao, et al.

The Journal of Clinical Investigation|January 16, 2026

Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentationHanchen Xu, Kevin Van der Jeught, Zhuolong Zhou, et al.

The Journal of Clinical Investigation|May 1, 2026

Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentationHanchen Xu, Kevin Van der Jeught, Zhuolong Zhou, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

British Journal of Cancer|April 19, 2025

Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancerXin Li, Kenza Mamouni, Rui Zhao, et al.

The Journal of Clinical Investigation|January 16, 2026

Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentationHanchen Xu, Kevin Van der Jeught, Zhuolong Zhou, et al.

The Journal of Clinical Investigation|May 1, 2026

Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentationHanchen Xu, Kevin Van der Jeught, Zhuolong Zhou, et al.

Pageof 4